Please assess the completion status of the following clinical trial:

Trial Title: 68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Suspected prostate cancer~* Planned prostate biopsy~* Able to provide written consent~* Karnofsky performance status of 50 (or ECOG/WHO equivalent)~Exclusion Criteria:~* Patients not capable of getting PET study due to weight, claustrophobia, or inability to lay still for the duration of the exam~* Metallic implants (contraindicated for MRI)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 68Ga RM2 first followed by 68Ga PSMA11 (Type: EXPERIMENTAL): Participant will be injected IV with 140 ±20% mBq of 68Ga RM2 and then within two weeks Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11
- 68Ga PSMA11 first followed by 68Ga RM2 (Type: EXPERIMENTAL): Participant will be injected IV with 3 to 7 mCi of 68Ga PSMA11 and then within two weeks Participant will be injected IV with 140 ±20% mBq of 68Ga RM2

Based on this trial design, predict the completion outcome and termination type (if applicable).